Lupin launches Generic PhosLo in the US

The company launched the drug following the approval from the US health regulator

id-10039602

Lupin's drug is the AB rated generic equivalent of Fresenius Medical Care North America's (Fresenius) PhosLo Gelcaps

Pharma major Lupin has announced that its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) has launched its Calcium Acetate Capsules, 667 mg (eq. 169 mg Calcium) having received final approval from the United States Food and Drug Administration (FDA).

Lupin's Calcium Acetate Capsules, 667 mg (eq. 169 mg Calcium) are the AB rated generic equivalent of Fresenius Medical Care North America's (Fresenius) PhosLo Gelcaps 667 mg (eq. 169 mg Calcium) and are indicated for the control of hyperphosphatemia in end stage renal failure.

PhosLo Gelcaps had annual US sales of $54.5 million (IMS MAT March, 2015).

 

 

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X